Tsai RM, Miller Z, Koestler M, et al. - In this randomized clinical trial involving 68 candidates (38 men [56%]; median age, 65 [range, 50-85] years), researchers tested the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease (AD) or the 4-repeat tauopathies (4RT) progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Severe hypersensitivity reactions were noted only in individuals with AD who received TPI-287, on the other hand, clinical worsening and biomarker changes were seen in those with PSP and CBS. Due to anaphylactoid reactions, TPI-287 was less tolerated in patients with AD than in patients with 4RT. The ability to reveal various tau therapeutic impacts in various tauopathy syndromes indicates that basket trials are a beneficial approach to tau therapeutic early clinical development.